7*24 Hotline：
Shenzhen Haiwang Bioengineering Co., Ltd. (000078)
In the past 20 years, based on the frontier of biopharmaceutical industry, Haiwang has actively promoted scientific and technological innovation, and has been developing continuously in the fields of pharmaceutical industry and bioengineering industry, and has achieved sustained and rapid development. As of 2010, Haiwang Group has a total assets of 10.1 billion, has four modern pharmaceutical industrial bases, two modern logistics bases, national enterprise technology center and post doctoral workstation, and can carry out technological innovation in the forefront of biopharmaceutical world, and its pharmaceutical products cover biomedical, chemical and traditional Chinese medicine modernization and other fields. After years of cultivation, the group's seaking biology, king of sea, and star stars of Haiwang are listed on Shenzhen Stock Exchange, Hong Kong Stock Exchange gem and New York exchange of the United States.
Haiwang has the most valuable brand in Chinese medicine industry, and the trademark of "Haiwang" is a well-known trademark in China. The "500 most valuable brand in China" jointly reviewed and issued by the World Economic Forum (WEF) in 2004, Haiwang ranked first in the pharmaceutical industry with its distinctive brand positioning and strong brand competitiveness, and became a model for the rapid improvement of brand value in Chinese medicine industry. Through the professional evaluation of world brand laboratory, 2004, 2005, 2006, 2007, 2008, 2009 and 2010 ranked the top in the Chinese pharmaceutical industry in the evaluation of "China's 500 most valuable brands" for seven consecutive years. In 2010, the brand value of "Haiwang" was RMB 16.655 billion. Haiwang has become a well-known brand with wide influence in the domestic health industry, and its comprehensive strength ranks in the forefront of the Chinese pharmaceutical industry.
Based on the basic idea of creating wealth for society, creating value for customers and creating opportunities for employees, Haiwang insists on people-oriented in management, respects human value and personality, pursues the common sustainable development of employees and enterprises, and builds a strategic human resource management system aiming at attracting talents, cultivating talents, retaining talents and creating space for talent development. In 2000, Haiwang Group was jointly awarded the title of "national enterprise technology center" by the national development and Reform Commission, the Ministry of finance, the General Administration of customs and the State Administration of taxation; in 2001, it was recognized as "national post doctoral research station" by the Ministry of personnel and the national post doctoral Administration Committee; in 2002, it won the "talent development achievement award" issued by Guangdong talent Association; in 2004 In 2006, it was awarded the title of "top ten Chinese independent innovation ability industries" by the State Bureau of statistics and China industry enterprise information release center; in 2007, it was ranked seventh in the fourth "South Weekend China (mainland) wealth creation list", The best public image in the sub list is the first and the best social responsibility is the third. In addition, Haiwang Group has more than 400 honors, such as "China famous trademark", "growing up top 100 enterprises in China", "top 100 enterprises with the most competitive high-tech", "top 50 listed companies with the most potential development in China" and "top 100 enterprises in Guangdong Province".
Haiwang will take market as the guidance, science and technology as the leading point, take innovation as the soul, aim at the world high-tech industry frontier, grasp the development trend of international high-tech, utilize the existing resource advantages, establish and perfect the pharmaceutical industry system, make the product development, production and marketing process systematize, standardize and intensively, expand the enterprise scale continuously, improve the economic benefits and resources of the enterprise Benefit, strive to become a leading domestic and international competitive awareness and ability of technology innovation pharmaceutical enterprises in the near future.
Health makes all efforts possible. Health is the foundation of achieving career, achieving happiness, achieving life and achieving future, and is the eternal pursuit and dream of mankind. The sea king is engaged in such a glorious cause as the maintenance of human health. It is the only goal of our king to contribute high quality products and services and strive to improve the quality of life of people.
The company was formerly Shenzhen Shekou Haiwang Bioengineering Co., Ltd. was established on December 13, 1992, approved by the Nanshan District People's Government of Shenzhen with the document shennanfu (1992) No.118. On July 25th, 1996, the public stock company was reorganized with the approval of Shenzhen Securities Regulatory Office in accordance with szbpf (1996) No. 68 document. On April 16th, 1997, the name of the joint stock company to be raised and established with the approval of Shenzhen Municipal Bureau of industry and commerce was Shenzhen Haiwang Bioengineering Co., Ltd. with a capital stock of 57.3 million yuan. On August 4, 1998, the CSRC approved the company to issue 1910000 RMB common shares to the public in the document of CSRC [1998] No. 214, and listed and traded on Shenzhen Stock Exchange on December 18th, 1998.
oil wellhead